Canaccord Genuity reiterated their buy rating on shares of Histogenics (NASDAQ:HSGX) in a research report report published on Thursday morning. Canaccord Genuity currently has a $4.00 price objective on the biotechnology company’s stock.
A number of other equities analysts have also recently commented on HSGX. Zacks Investment Research raised Histogenics from a hold rating to a buy rating and set a $2.00 target price on the stock in a report on Wednesday, August 23rd. HC Wainwright reaffirmed a buy rating and issued a $3.50 target price on shares of Histogenics in a report on Tuesday, November 21st.
Shares of Histogenics (HSGX) opened at $2.04 on Thursday. Histogenics has a 52 week low of $1.45 and a 52 week high of $2.40. The company has a market capitalization of $49.59, a price-to-earnings ratio of -1.48 and a beta of 1.43.
Histogenics Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.